TY  - JOUR
A1  - ,  
T1  - Antagonism between Ghrelin / GH secretagogues and somatostatin in arcuate and periventricular nuclei in prepubertal female rats
JO  - Eur. J. Anat.
SN  - 1136-4890
Y1  - 2009
VL  - 13
SP  - 83
EP  - 90
UR  - http://www.eurjanat.com/web/paper.php?id=09020083
KW  - ghrelin
KW  - growth hormone
KW  - growth hormone releasing factor
KW  - growth hormone secretagogue
KW  - histidyl dextro tryptophylalanyltryptophyl dextro phenylalanyllysinamide
KW  - protein fos
KW  - somatostatin
KW  - animal experiment
KW  - arcuate nucleus
KW  - article
KW  - drug activity
KW  - electroencephalogram
KW  - female
KW  - hormone blood level
KW  - nonhuman
KW  - protein expression
KW  - rat
KW  - thalamus midline nucleus
N2  - Combined growth hormone-releasing hormone (GHRH) and growth hormone secretogogues (GHS) have been used alone or in combination with somatostatin (SRIF) to study the pituitary growth hormone (GH) reserve in adults with GH deficiency, but not in children, owing to the possible adverse effects of these treatments. The study aimed to assess the response of the arcuate and periventricular hypothalamic nuclei, using Fos protein as a marker of neuron activity, and to compare that response with the GH response to different stimuli in the presence or absence of SRIF in prepubertal female rats. Rats received the following intraperitoneal stimuli: GHRH (1?g/kg), GHRP-6 (1 ?g/kg), ghrelin (1 ?g/kg), and GHRH combined with either GHRP-6 or ghrelin, with or without SRIF pretreatment 90 minutes prior to stimulus. The animals were decapitated at different intervals; trunk blood was obtained for the measurement of GH levels using a radioimmunoassay technique, and hypothalamic sections were processed for immunochemical determination of Fos protein expression. In the arcuate nucleus, except for GHRP-6 all stimuli increased Fos protein activity in the absence of SRIF pretreatment; the same effect was achieved by pretreatment with SRIF, although this pretreatment prevented the increase in neuronal activity following all stimuli, except that with GHRH + GHRP-6. In the periventricular nucleus, stimulus with GHRH, GHRP-6, ghrelin and GHRH+ghrelin caused a decline in Fos protein expression in the absence of SRIF, whereas SRIF pretreatment prompted a decrease in Fos protein expression that was counteracted by GHRP6 and GHRH + ghrelin. Peak serum GH values were recorded 15 minutes after the administration of GHRH+ghrelin and GHRH + GHRP-6. SRIH pretreatment inhibited GH release, with a subsequent «escape» and lack of response to stimulation which lasted at least 30 minutes, except following the administration of GHRH. The results suggest that all these actions may be due to functional antagonism between ghrelin/ GH secretagogues and somatostatin.
ER  -